← Back to Analyst Consensus 
DNLI Buy
Denali Therapeutics Inc.
Current Price —
Implied Upside —
Analysts 26
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 4, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 25, 2026 | B. Riley Securities | maintain | Buy → Buy | — | 55% |
| Aug 7, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Jul 23, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Jul 16, 2026 | Deutsche Bank | maintain | Buy → Buy | — | 57% |
| May 26, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| May 14, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| May 11, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| May 8, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Apr 22, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Apr 7, 2026 | Baird | maintain | Outperform → Outperform | — | 55% |
| Mar 26, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Mar 26, 2026 | Goldman Sachs | maintain | Buy → Buy | — | 54% |
| Mar 26, 2026 | Stifel | maintain | Buy → Buy | — | 53% |
| Mar 26, 2026 | Baird | maintain | Outperform → Outperform | — | 55% |
| Mar 26, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 25, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Mar 2, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Feb 24, 2026 | Wolfe Research | initiate | — → Peer Perform | $0 | 53% |
| Feb 6, 2026 | BTIG | reiterate | Buy → Buy | $32 | 52% |
| Dec 11, 2025 | Wedbush | maintain | Outperform → Outperform | $30 | 58% |
| Dec 5, 2025 | Wedbush | maintain | Outperform → Outperform | $31 | 58% |
| Dec 5, 2025 | BTIG | reiterate | Buy → Buy | $32 | 52% |
| Nov 4, 2025 | JP Morgan | maintain | Overweight → Overweight | $26 | 54% |
| Sep 8, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| Aug 18, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $30 | 54% |
| May 19, 2025 | B of A Securities | maintain | Buy → Buy | $27 | 53% |
| May 8, 2025 | Baird | maintain | Outperform → Outperform | $29 | 55% |
| May 7, 2025 | Wedbush | maintain | Outperform → Outperform | $30 | 58% |
| May 7, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $32 | 44% |
| Mar 10, 2025 | B of A Securities | maintain | Buy → Buy | $28 | 53% |
| Mar 5, 2025 | B. Riley Securities | reiterate | Buy → Buy | $35 | 55% |
| Mar 3, 2025 | Oppenheimer | maintain | Outperform → Outperform | $42 | 52% |
| Feb 28, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $87 | 44% |
| Feb 11, 2025 | Deutsche Bank | initiate | — → Buy | $31 | 57% |
| Jan 28, 2025 | Goldman Sachs | maintain | Buy → Buy | $40 | 54% |
| Jan 7, 2025 | JP Morgan | maintain | Overweight → Overweight | $24 | 54% |
| Jan 7, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $87 | 44% |
| Jan 7, 2025 | Baird | initiate | — → Outperform | $31 | 55% |
| Jan 3, 2025 | William Blair | initiate | — → Outperform | $0 | 48% |
| Dec 16, 2024 | Stifel | upgrade | Hold → Buy | $37 | 53% |
| Nov 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $90 | 44% |
| Nov 1, 2024 | Jefferies | maintain | Buy → Buy | $45 | 52% |
| Oct 11, 2024 | JP Morgan | maintain | Overweight → Overweight | $28 | 54% |
| Sep 9, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $35 | 50% |
| Sep 4, 2024 | HC Wainwright& Co. | reiterate | Buy → Buy | $90 | — |
| Sep 4, 2024 | B of A Securities | maintain | Buy → Buy | $29 | 53% |
| Aug 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $90 | 44% |
| Aug 5, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $90 | 44% |
| Aug 2, 2024 | Citigroup | maintain | Buy → Buy | $32 | 54% |
| Aug 2, 2024 | Wedbush | maintain | Outperform → Outperform | $26 | 58% |
Price Target Trend
Jun 5, 2026 Latest: $35.5 Oct 25, 2026
EPS Estimates
+1y $-2.42
Lo: $-3.20 Hi: $-1.70
17 analysts ▲1
0q $-0.37
Lo: $-0.88 Hi: $0.38
17 analysts ▲1
0y $-2.23
Lo: $-2.75 Hi: $-0.22
17 analysts +1q $-0.62
Lo: $-0.80 Hi: $-0.46
17 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days